Sanofi $2.2 billion vaccine deal comes alongside FDA setback

Sanofi agreed to buy Dynavax Technologies Corp. for about $2.2 billion, as it seeks to expand a vaccines business currently ...

Sanofi-Dynavax: A Conservative Vaccine Deal With Upside Tail Risk

Sanofi acquires Dynavax for $2.2B, boosting its vaccine portfolio with HEPLISAV-B and a shingles candidate. Click for my ...

Press Release: Sanofi to acquire Dynavax, adding a marketed adult hepatitis B vaccine and phase 1/2 shingles candidate to the pipeline

Sanofi to acquire Dynavax, adding a marketed adult hepatitis B vaccine and phase 1/2 shingles candidate to the pipeline Paris, December 24, 2025.

Sanofi Makes $2.2 Billion Bet On Adult Vaccines With Dynavax Buy

Sanofi (SNY) to acquire Dynavax Technologies (DVAX) for $15.50 per share in cash, expanding its presence in adult ...
EconoTimes

Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio

Sanofi has announced an agreement to acquire U.S.-based vaccines company Dynavax Technologies in an all-cash transaction ...